Second-line end points of the TRICOTEL trial assessing atezolizumab plus vemurafenib and cobimetinib in melanoma with central nervous system metastases appear consistent with primary efficacy end points.
2023
Incidence of in situ and invasive cutaneous melanomas during the pandemic
About The Study: Researchers identified decreases of in situ and invasive melanoma diagnoses during 2020, which may reflect decreased skin cancer screening examinations or access to dermatologic care during the pandemic, both of which may lead to reduced melanoma diagnoses.
Medication for heart conditions improves melanoma treatment
A collaborative study led by IRB Barcelona, Navarrabiomed and the Institute of Neurosciences CSIC-UMH shows that the administration of ranolazine, a drug currently used to treat heart conditions, improves the efficacy of current therapies for melanoma in mouse models of the disease.
Fecal Microbiota Different Between Patients With Melanoma, Controls
Fecal microbiota profiles were significantly different between patients with melanoma and controls, and between patients with early-stage and late-stage melanoma, according to study results published in JAMA Dermatology.